EQS-News: Pentixapharm Holding AG / Key word (s): Conference/Scientific publication Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 ...

Conference/Scientific publicationPentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 25.04.2025 / 15:39 CET/CESTThe issuer is solely responsible ...

A joint research team has developed a modular protein adapter technology that enables the stable attachment of various ...

Prostate cancer has distinct genetic properties in different groups of men that can be targeted to improve patient outcomes, UVA Cancer Center researchers have discovered.

Highlights of BioNTech’s oncology programs to be presented at AACR 2025: ...

South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

The body's immune system mistakenly produces "autoantibodies," or antibodies that attack its own tissues and proteins. In the case of myasthenia gravis, the body produces autoantibodies that ...

Get Instant Summarized Text (Gist) A novel approach using CAR-M (Chimeric Antigen Receptor Macrophages) has been developed to address the limitations of CAR-T therapy in treating solid tumors. By ...

Introduction: Chimeric antigen receptor (CAR ... By engineering epitopes of TSHR as the binding domain, our CAAR was able to bind to anti-TSHR antibodies and B cell receptors. Results: These TSHR CAAR ...